Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments

BACKGROUND: Despite extensive clinical use, the mechanisms that lead to therapeutic resistance to anti-programmed cell-death (PD)-1 monoclonal antibodies (mAbs) remain elusive. Here, we sought to determine how interactions between the Fc region of anti-PD-1 mAbs and Fcγ receptors (FcγRs) affect ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno-Vicente, Julia, Willoughby, Jane E, Taylor, Martin C, Booth, Steven G, English, Vikki L, Williams, Emily L, Penfold, Christine A, Mockridge, C Ian, Inzhelevskaya, Tatyana, Kim, Jinny, Chan, H T Claude, Cragg, Mark S, Gray, Juliet C, Beers, Stephen A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753441/
https://www.ncbi.nlm.nih.gov/pubmed/35017153
http://dx.doi.org/10.1136/jitc-2021-003735

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753441/
https://www.ncbi.nlm.nih.gov/pubmed/35017153
http://dx.doi.org/10.1136/jitc-2021-003735

Ejemplares similares